

---

**SUMMARY OF PRODUCT CHARACTERISTICS**

---

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (AT/ BE/ BG/ CY/ CZ/ DE/ ES/ FR/ GR/ HR/ HU/ IE/ IT/ LT/ LV/ LU/ MT/ NL/ PL/ PT/ RO/ SI/ SK/ UK )  
Veytosal Vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (NO/DK/ FI/ IS)  
Phoscobal vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (SE)  
Vey Tosal (EE)

**1. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains

**Active substances:**

Butafosfan:	100.00 mg
Cyanocobalamin (vitamin B12):	0.05 mg

**Excipient:**

Benzyl alcohol (E 1519)	20.00 mg
-------------------------	----------

For the full list of excipients, see section 6.1

**2. PHARMACEUTICAL FORM**

Solution for injection.  
Clear, pink solution.

**3. CLINICAL PARTICULARS****3.1 Target species**

Cattle, horses, dogs and cats.

**3.2 Indications for use, specifying the target species**

As supportive treatment of metabolic or reproductive disorders, when supplementation of phosphorous and cyanocobalamin is needed.

In case of peri-parturient metabolic disorders, tetany and paresis (milk fever), the product should be administered in addition to magnesium and calcium, respectively.

Supporting muscle function in the presence of deficiencies of phosphorous and/or cyanocobalamin.

**3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

**3.4 Special warnings for each target species**

It is recommended to determine the cause(s) of the metabolic or reproductive disorders to define the most appropriate measures of prevention and treatment and the need for a therapy with supplemental phosphorus and vitamin B<sub>12</sub>.

### 3.5 Special precautions for use

#### Special precautions for use in animals

Due to a deficiency in glucuronidating metabolic pathways in cats, which are involved in benzyl alcohol metabolism, this veterinary medicinal product should be used with caution and the recommended dose should be strictly observed in this species.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

This veterinary medicinal product contains benzyl alcohol which may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to benzyl alcohol should avoid contact with the veterinary medicinal product.

This product may cause irritation of skin, eyes, and mucous membranes. Such contact with the product should be avoided. In case of accidental exposure, rinse the affected area thoroughly with water.

Do not eat, drink or smoke while handling this product.

Wash hands after use.

### 3.6 Adverse reactions (frequency and seriousness)

In cats, following subcutaneous injection in the interscapular region, reactions at injection site (swelling, oedema, erythema and induration) can be observed.

### 3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established in pregnant and lactating cows, mares, bitches and queens. However, its use during pregnancy and lactation in those species should not pose any particular problem.

### 3.8 Interaction with other medicinal products and other forms of interaction

None known.

### 3.9 Amounts to be administered and administration route

Cattle, horses: for intravenous use

Dogs and cats: for intravenous, intramuscular and subcutaneous use

Animal species / sub-category	Butafosfan (mg/kg)	Vitamin B <sub>12</sub> (µg/kg)	Product (ml/kg)	Route of administration
Cattle	2.0 - 5.0	1.0 - 2.5	0.02 - 0.05	IV
Calves	3.3 - 5.6	1.65 - 2.8	0.033 - 0.056	IV
Horses	2.0 - 5.0	1.0 - 2.5	0.02 - 0.05	IV
Foals	3.3 - 5.6	1.65 - 2.8	0.033 - 0.056	IV
Dogs	2.5 - 25	1.25 - 12.5	0.025-0.25	IV, IM, SC
Cats	10 - 50	5.0 - 25	0.1-0.5	IV, IM, SC

Repeat once daily, if necessary.

The cap may be safely punctured up to 40 times. If more than 40 broachings are required, use of a draw off needle is recommended.

It is recommended to use 100 ml packaging for treatment of dogs and cats.

### 3.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

None known.

### 3.11 Withdrawal period(s)

Cattle, horses:

Meat and offal: zero days

Milk: zero hours

## 4. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: mineral supplements, other mineral products, combinations.

ATCvet code: QA12CX99.

### 5.1 Pharmacodynamic properties

Butafosfan is an organic phosphorus source for animal metabolism. Among others phosphorus is relevant for energy metabolism. It is essential for gluconeogenesis since most intermediates of that process need to be phosphorylated. Direct pharmacological effects of butafosfan beyond simple phosphorus substitution have additionally been postulated.

Cyanocobalamin is a co-enzyme in the biosynthesis of glucose from propionate. Further it serves as a co-factor to enzymes important in fatty acid synthesis and is important for maintenance of normal haemopoiesis, protection of the liver, and maintenance of muscle tissue, healthy skin, brain and pancreatic metabolism. It belongs to the class of water-soluble B vitamins synthesized by the microbiotic flora in the digestive system of the animals (reticulorumen and large intestine). Owing to the microbes' own requirements, the synthesis usually does not produce sufficient quantities to cover the needs of the entire animal organism. Marked deficiencies occur rarely, even in case of an inadequate supply with cyanocobalamin.

The exact mode of action of cyanocobalamin and butafosfan in combination is not fully understood. Various effects on bovine lipid metabolism of cyanocobalamin and butafosfan in combination have been observed in clinical studies including reduced serum levels of ketosis-related non-esterified fatty acids and  $\beta$ -hydroxybutyric acid.

### 5.2 Pharmacokinetic particulars

Following intravenous administration to cattle butafosfan is distributed in the extravascular space within minutes and rapidly excreted from the body unchanged. The elimination half-life is 83 to 116 minutes. Within twelve hours after intravenous administration a mean of 74 - 77% of the parent compound is recovered in the urine.

Only traces of butafosfan are found in the milk. Hepatic metabolic degradation was not detected. Butafosfan is rapidly absorbed and eliminated after parenteral administration in all target animal species.

The metabolism of cyanocobalamin is complex and is associated closely with that of folic acid and of ascorbic acid. Vitamin B<sub>12</sub> is stored in significant amounts in the liver, further storage sites include kidney, heart, spleen and brain. Tissue half-life of vitamin B<sub>12</sub> is 32 days. In ruminants vitamin B<sub>12</sub> is excreted primarily in the faeces and in smaller amounts in the urine.

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 List of excipients

Benzyl alcohol (E 1519)

Sodium hydroxide (for pH adjustment)

Hydrochloric acid, dilute (for pH adjustment)

Water for injections

## **5.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **5.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: 28 days.

## **5.4 Special precautions for storage**

Keep the vial in the outer carton in order to protect from light.

## **5.5 Nature and composition of immediate packaging**

Amber glass vial type II with bromobutyl rubber stopper and aluminium cap with a flip-off seal.

Pack sizes:

Cardboard box with 1 vial of 100 ml

Cardboard box with 1 vial of 250 ml

Not all pack sizes may be marketed.

## **5.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **6. MARKETING AUTHORISATION HOLDER**

Veyx-Pharma GmbH  
Soehreweg 6  
34639 Schwarzenborn  
Germany

## **7. MARKETING AUTHORISATION NUMBER(S)**

## **8. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

## **9. DATE OF REVISION OF THE TEXT**

**LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****{Folding box}****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (AT/ BE/ BG/ CY/ CZ/ DE/ ES/ FR/ GR/ HR/ HU/ IE/ IT/ LT/ LV/ LU/ MT/ NL/ PL/ PT/ RO/ SI/ SK/ UK) )  
Veytosol Vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (NO/DK/ FI/ IS)  
Phoscobal vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (SE)  
Vey Tosal (EE)  
Butafosfan / cyanocobalamin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains

**Active substances:**

Butafosfan:	100.00 mg
Cyanocobalamin (vitamin B12):	0.05 mg

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, horses, dogs and cats

**6. INDICATION(S)****7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Route of administration:

Cattle, horses: IV

Dogs and cats: IV, IM, SC

Dose

Cattle and horses: 0.02 - 0.05 ml product/kg b.w.

Calves and foals: 0.033 - 0.056 ml product/kg b.w.

Dogs: 0.025-0.25 ml product/kg b.w.

Cats: 0.1-0.5 ml product/kg b.w.

**8. WITHDRAWAL PERIOD (S)**

Withdrawal periods:

Cattle, horses:

Meat and offal: zero days

Milk: zero hours

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use within 28 days.

Once opened use by.....

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Veyx-Pharma GmbH  
Soehreweg 6  
34639 Schwarzenborn  
Germany

**16. MARKETING AUTHORISATION NUMBER(S)****17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

{Label}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats  
(AT/ BE/ BG/ CY/ CZ/ DE/ ES/ FR/ GR/ HR/ HU/ IE/ IT/ LT/ LV/ LU/ MT/ NL/ PL/ PT/ RO/ SI/  
SK/ UK )

Veytosol Vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats  
(NO/DK/ FI/ IS)

Phoscobal vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (SE)

Vey Tosal (EE)

Butafosfan / cyanocobalamin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains

**Active substances:**

Butafosfan: 100.00 mg

Cyanocobalamin (vitamin B12): 0.05 mg

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

100 ml

250 ml

**5. TARGET SPECIES**

Cattle, horses, dogs and cats

**6. INDICATION(S)****7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Cattle, horses: IV

Dogs and cats: IV, IM, SC

**8. WITHDRAWAL PERIOD (S)**

Withdrawal periods:

Cattle, horses:

Meat and offal: zero days

Milk: zero hours

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use within 28 days

Once opened use by.....

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY****13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”****15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Veyx-Pharma GmbH  
Soehreweg 6  
34639 Schwarzenborn  
Germany

**16. MARKETING AUTHORISATION NUMBER(S)****17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**PACKAGE LEAFLET:**

**Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats**  
(AT/ BE/ BG/ CY/ CZ/ DE/ ES/ FR/ GR/ HR/ HU/ IE/ IT/ LT/ LV/ LU/ MT/ NL/ PL/ PT/ RO/ SI/ SK/  
UK )

**Veytosal Vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats**  
(NO/DK/ FI/ IS)

**Phoscobal vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (SE)**  
**Vey Tosal (EE)**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE , IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Veyx-Pharma GmbH  
Soehreweg 6  
34639 Schwarzenborn  
Germany

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats  
(AT/ BE/ BG/ CY/ CZ/ DE/ ES/ FR/ GR/ HR/ HU/ IE/ IT/ LT/ LV/ LU/ MT/ NL/ PL/ PT/ RO/ SI/ SK/  
UK )

Veytosal Vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (NO/DK/  
FI/ IS)

Phoscobal vet 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats (SE)

Vey Tosal (EE)

Butafosfan, cyanocobalamin

**3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS**

Each ml contains

**Active substances:**

Butafosfan:	100.00 mg
Cyanocobalamin (vitamin B12):	0.05 mg

**Excipient:**

Benzyl alcohol (E 1519)	20.00 mg
-------------------------	----------

Clear, pink solution.

**4. INDICATION(S)**

As supportive treatment of metabolic or reproductive disorders, when supplementation of phosphorous and cyanocobalamin is needed.

In case of peri-parturient metabolic disorders, tetany and paresis (milk fever), the product should be administered in addition to magnesium and calcium, respectively.

Supporting muscle function in the presence of deficiencies of phosphorous and/or cyanocobalamin.

**5. CONTRAINDICATIONS**

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

**6. ADVERSE REACTIONS**

In cats, following subcutaneous injection in the interscapular region, reactions at injection site (swelling, oedema, erythema and induration) can be observed.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

**7. TARGET SPECIES**

Cattle, horses, dogs and cats.

**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Cattle, horses: for intravenous use

Dogs and cats: for intravenous, intramuscular and subcutaneous use

Animal species / sub-category	Butafosfan (mg/kg)	Vitamin B <sub>12</sub> (µg/kg)	Product (ml/kg)	Route of administration
Cattle	2.0 - 5.0	1.0 - 2.5	0.02 - 0.05	IV
Calves	3.3 - 5.6	1.65 - 2.8	0.033 - 0.056	IV
Horses	2.0 - 5.0	1.0 - 2.5	0.02 - 0.05	IV
Foals	3.3 - 5.6	1.65 - 2.8	0.033 - 0.056	IV
Dogs	2.5 - 25	1.25 - 12.5	0.025-0.25	IV, IM, SC
Cats	10 - 50	5.0 - 25	0.1-0.5	IV, IM, SC

Repeat once daily, if necessary.

**9. ADVICE ON CORRECT ADMINISTRATION**

The cap may be safely punctured up to 40 times. If more than 40 broachings are required, use of a draw off needle is recommended.

It is recommended to use 100 ml packaging for treatment of dogs and cats.

**10. WITHDRAWAL PERIOD(S)**

Cattle, horses:

Meat and offal: zero days

Milk: zero hours

**11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the vial after EXP. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days.

## **12. SPECIAL WARNING(S)**

### Special warnings for each target species:

It is recommended to determine the cause(s) of the metabolic or reproductive disorders to define the most appropriate measures of prevention and treatment and the need for a therapy with supplemental phosphorus and vitamin B<sub>12</sub>.

Due to a deficiency in glucuronidating metabolic pathways in cats, which are involved in benzyl alcohol metabolism, this veterinary medicinal product should be used with caution and the recommended dose should be strictly observed in this species.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product contains benzyl alcohol which may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to benzyl alcohol should avoid contact with the veterinary medicinal product.

This product may cause irritation of skin, eyes, and mucous membranes. Such contact with the product should be avoided. In case of accidental exposure, rinse the affected area thoroughly with water.

Do not eat, drink or smoke while handling this product.

Wash hands after use.

### Pregnancy and Lactation:

The safety of the veterinary medicinal product has not been established in pregnant and lactating cows, mares, bitches and queens. However, its use during pregnancy and lactation in those species should not pose any particular problem.

### Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

## **15. OTHER INFORMATION**

Amber glass vial type II with bromobutyl rubber stopper and aluminium cap with a flip-off seal.

Pack sizes:

Cardboard box with 1 vial of 100 ml

Cardboard box with 1 vial of 250 ml

Not all pack sizes may be marketed.

**België/Belgique/Belgien**

{Nom/Naam/Name}  
 <{Adresse/Adres/Anschrift }  
 BE-0000 {Localité/Stad/Stadt}>  
 Tél/Tel: + {N° de téléphone/Telefoonnummer/  
 Telefoonnummer}  
 <{E-mail}>

**Република България**

{Наименование}  
 <{Адрес}  
 BG {Град} {Пощенски код}>  
 Тел: + 359 {Телефонен номер}  
 <{E-mail}>

**Česká republika**

□ Název □  
 <□ Adresa □  
 CZ  
 □ město □>  
 Tel: +□ telefonní číslo □  
 <{E-mail}>

**Danmark**

{Navn}  
 <{Adresse}  
 DK-0000 {by}>  
 Tlf: + {Telefoonnummer}  
 <{E-mail}>

**Deutschland**

{Name}  
 <{Anschrift}  
 DE-00000 {Stadt}>  
 Tel: + {Telefoonnummer}  
 <{E-mail}>

**Eesti**

(Nimi)  
 <(Aadress)  
 EE - (Postiindeks) (Linn)>  
 Tel: +(Telefoninumber)  
 <{E-mail}>

**Ελλάδα**

{Όνομα}  
 <{Διεύθυνση}  
 EL-000 00 {πόλη}>  
 Τηλ: + {Αριθμός τηλεφώνου}  
 <{E-mail}>

**Lietuva**

{pavadinimas}  
 <{adresas}  
 LT {pašto indeksas} {miestas}>  
 Tel: +370 {telefono numeris}  
 <{E-mail}>

**Luxembourg/Luxemburg**

{Nom}  
 <{Adresse}  
 L-0000 {Localité/Stadt}>  
 Tél/Tel: + {N° de téléphone/Telefoonnummer}  
 <{E-mail}>

**Magyarország**

{Név}  
 <{Cím}  
 HU-0000 {Város}>  
 Tel.: + {Telefonszám}  
 <{E-mail}>

**Malta**

{Isem}  
 <{Indirizz}  
 MT-0000 {Belt/Raħal}>  
 Tel: + {Numru tat-telefon}  
 <{E-mail}>

**Nederland**

{Naam}  
 <{Adres}  
 NL-0000 XX {stad}>  
 Tel: + {Telefoonnummer}  
 <{E-mail}>

**Norge**

{Navn}  
 <{Adresse}  
 N-0000 {poststed}>  
 Tlf: + {Telefoonnummer}  
 <{E-mail}>

**Österreich**

{Name}  
 <{Anschrift}  
 A-00000 {Stadt}>  
 Tel: + {Telefoonnummer}  
 <{E-mail}>

**España**

{Nombre}  
 <{Dirección}  
 ES-00000 {Ciudad}>  
 Tel: + {Teléfono}  
 <{E-mail}>

**France**

{Nom}  
 <{Adresse}  
 FR-00000 {Localité}>  
 Tél: + {Numéro de téléphone}  
 <{E-mail}>

**Hrvatska**

{Ime}  
 <{Adresa}  
 {Poštanski broj} {grad}>  
 Tel: + {Telefonski broj}  
 <{e-mail}>

**Ireland**

{Name}  
 <{Address}  
 IE - {Town} {Code for Dublin}>  
 Tel: + {Telephone number}  
 <{E-mail}>

**Ísland**

{Nafn}  
 <{Heimilisfang}  
 IS-000 {Borg/Bær}>  
 Sími: + {Símanúmer}  
 <{Netfang}>

**Italia**

{Nome}  
 <{Indirizzo}  
 IT-00000 {Località}>  
 Tel: + {Numero di telefono}>  
 <{E-mail}>

**Κύπρος**

{Όνομα}  
 <{Διεύθυνση}  
 CY-000 00 {πόλη}>  
 Τηλ: + {Αριθμός τηλεφώνου}  
 <{E-mail}>

**Latvija**

{Nosaukums}  
 <{Adrese}  
 {Pilsēta}, LV {Pasta indekss }>  
 Tel: + {Telefona numurs}  
 <{E-mail}>

**Polska**

{Nazwa/ Nazwisko:  
 <{Adres:  
 PL – 00 000 {Miasto:}>  
 Tel.: + {Numer telefonu:  
 <{E-mail}>

**Portugal**

{Nome}  
 <{Morada}  
 PT-00000000 {Cidade}> Tel:  
 + {Número de telefone}  
 <{E-mail}>

**România**

{Nume}  
 <{Adresă}  
 {Oraș} {Cod poștal} – RO>  
 Tel: + {Număr de telefon}  
 <{E-mail}>

**Slovenija**

{Ime}  
 <{Naslov}  
 SI-0000 {Mesto}>  
 Tel: + {telefonska številka}  
 <{E-mail}>

**Slovenská republika**

{Meno}  
 <{Adresa}  
 SK-000 00 {Mesto}>  
 Tel: + {Telefónne číslo}  
 <{E-mail}>

**Suomi/Finland**

{Nimi/Namn}  
 <{Osoite/Adress}  
 FI-00000 {Postitoimipaikka/Stad}>  
 Puh/Tel: + {Puhelinnumero/Telefonnummer}  
 <{E-mail}>

**Sverige**

{Namn}  
 <{Adress}  
 SE-000 00 {Stad}>  
 Tel: + {Telefonnummer}  
 <{E-mail}>

**United Kingdom (Northern Ireland)**

{Name}  
 <{Address}  
 {Town} {Postal code} – UK>  
 Tel: + {Telephone number}  
 <{E-mail}>